# Acid-base & chloride

## Normal ranges

- pH: *7.35 -- 7.45*
- PaCO~2~: *4.6 -- 6.0 kPa; 1 kPa = 7.5 mmHg*
- HCO~3~: *22 -- 30 mM*
- BE: *± 2 mM*

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  pH=-log[H^{+}]
  (\#eq:pH1)
\end{equation}

\begin{equation}
  H^{+} = 10^{pH}
  (\#eq:pH2)
\end{equation}
    </div>\EndKnitrBlock{eqnpanel}


## Adaptation

Metabolic adaptation to respiratory alkalosis:  

+  acute (5 -- 10 mins) HCO~3~ 16 -- 18 mM *buffering by serum HCO~3~* 
+  chronic (2 -- 3 days) HCO~3~ 12 -- 15 mM *renal excretion of HCO3* 

Respiratory adaptation:  

+  for each mM HCO~3~ \< 25 PaCO~2~ should drop by... 0.16 kPa (1.2 mmHg) 
+  for each mM HCO~3~ \> 25 PaCO~2~ should rise by... 0.08 kPa (0.6 mmHg) 
+  Winter's formula: PaCO2 (mmHg) = (1.5 × HCO~3~) + 8 +/- 2 *(in metabolic acidosis)*  


## Metabolic alkalosis (& chloride homeostasis)  

### Causes of a metabolic alkalosis  

<!-- +  low ECF volume = chloride-depletion / contractional = chloride-responsive  -->
<!--     +  *vomiting / NG losses*  -->
<!--     +  *loop / thiazide diuretics \**  -->
<!--     +  *Bartter's / Gitelman's \**  -->
<!--     +  *colonic villous adenoma / congenital chloride diarrhoea / high-volume ileostomy (rare)*   -->

<!-- +  normal ECF volume = chloride-resistant  -->
<!--     +  renal H + loss  -->
<!--         +  *true mineralocorticoid XS (low-renin / high-renin)*  -->
<!--         +  *apparent mineralocorticoid XS (and Liddle's)*  -->
<!--         +  *Cushings*  -->
<!--         +  *post-hypercapnic alkalosis (UCl \< 10 mM)*  -->
<!--         +  *milk-alkali syndrome*   -->
<!--     +  intracellular H + shift  -->
<!--         +  *hypokalaemia*   -->

<table>
<tbody>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="4"> LOW ECF VOLUME = CHLORIDE-DEPLETION / CHLORIDE-RESPONSIVE </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="2"> GI chloride loss </td>
   <td style="text-align:left;"> vomiting / NG losses </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> colonic villous adenoma / congenital chloride diarrhoea / high-volume ileostomy (rare) </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="2"> renal chloride loss </td>
   <td style="text-align:left;"> loop / thiazide diuretics * </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> Bartter / Gitelman * </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="6"> NORMAL ECF VOLUME = CHLORIDE-RESISTANT </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="5"> renal H + loss </td>
   <td style="text-align:left;"> true mineralocorticoid XS (low-renin / high-renin) </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> apparent mineralocorticoid XS (and Liddle’s) </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> Cushings </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> post-hypercapnic alkalosis (UCl &lt; 10 mM) </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> milk-alkali syndrome </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;"> intracellular H + shift </td>
   <td style="text-align:left;"> hypokalaemia </td>
  </tr>
</tbody>
</table>

In chloride-responsive states UCl \< 10 mM *(\* except diuretics / Gitelman / Barrter)*.

UCl will be low (\< 10 mM) if prior use of diuretics.

In chloride-resistant states, UCl \> 10 -- 30 mM *(\* also with diuretics / Gitelman / Barrter)*.

Post-hypercapnic alkalosis occurs if chronic hypercapnia suddenly corrected (e.g. by mechanical ventilation).

The milk-alkali syndrome is the triad of hypercalcaemia, metabolic alkalosis and ingestion of large quantities of calcium with alkali; hypercalcaemia increases renal bicarbonate reabsorption (exacerbating alkalosis).


### Chloride

U~Cl~ NR = 100 -- 250 mmol / 24 hrs

Increased in: *diuretics, Bartter, Gitelman, corticosteroids*.    

Decreased in: *vomiting, villous adenoma, congenital chloride diarrhoea, diuretics (pause on clinic day in diuretic abuse)*.    


#### Chloride-depletion alkalosis

In chloride depletion, reduced ECF volume leads to reduced GFR (less filtered NaHCO~3~) and increased Na reabsorption. Thus NaHCO~3~ reabsorption is increased. Increased distal Na reabsorption leads to increased acid excretion.

Therefore, after vomiting, an acid urine is produced (paradoxically) in the face of a metabolic alkalosis. Treatment is volume expansion with NaCl and correction of hypoK.

Urine electrolytes after vomiting:

+  early *(\< 3 days)* : pH \> 6.5, high Na, high K, low Cl, high HCO~3~ (*all high except chloride)*
+  late *(day 4+)* : pH \< 5.5, low Na, low K, low Cl, low HCO~3~ *(all low)*

Early after vomiting, metabolic alkalosis means that XS HCO~3~ is filtered, and the kidney cannot reabsorb this. Therefore bicarbonaturia drives natriuresis and kaliuresis (from increased distal Na delivery +/- volume contraction simulating aldosterone). By day 4, the kidney has upregulated ability to reabsorb HCO~3~, so natriuresis and kaliuresis abates, with paradoxical acid urine.

UCl is persistently low after vomiting (and is a useful test for surreptitious vomiting).

## Metabolic acidosis

### Anion & osmolar gaps

Metabolic acidoses are classified as wide-anion-gap (WGMA) or normal-anion-gap (= hyperchloraemic, HCMA).  In WGMA, the acidosis is caused by an exogenous acid present in plasma.  This is not measured directly, but will manifest as an apparent "anion gap".  

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  \text{anion gap, } AG=P_{Na}-P_{HCO_{3}}-P_{Cl}
  (\#eq:AGap)
\end{equation}

NB some people also include P~K~ in the calculation.  
    
\begin{equation}
  \text{corrected anion gap, } cAG=AG+\frac{40-P_{albumin}}{4}
  (\#eq:cAGap)
\end{equation}
    
NB ADD ON to correct for hypoalbuminaemia.  
    </div>\EndKnitrBlock{eqnpanel}

A normal AG is 12 ± 2 (or 16 ± 2 if include K^+^ in the calculation).  

'Deltas' are calculated by comparing to expected normal values (for AG or HCO~3~).  

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  \text{delta anion gap, } \Delta AG=AG-12
  (\#eq:DelAGap)
\end{equation}

\begin{equation}
  \text{delta bicarbonate, } \Delta HCO_{3}=25-P_{HCO{3}}
  (\#eq:DelHCO)
\end{equation}

\begin{equation}
  \text{delta ratio, } =\frac{\Delta AG}{\Delta HCO_{3}}
  (\#eq:DelRatio)
\end{equation}

\begin{equation}
  \text{delta delta, } \Delta \Delta = \Delta AG - \Delta HCO_{3} \text{ (in ketoacidosis)}\\
  \text{delta delta, } \Delta \Delta = (0.6 \times \Delta AG) - \Delta HCO_{3} \text{ (in lactic acidosis)}\\
  (\#eq:deltadelta)
\end{equation}</div>\EndKnitrBlock{eqnpanel}

Normal range for delta ratio (ΔAG / ΔHCO~3~) is 1 -- 2.  

Osmolar gaps are used to identify exogenous or un-measured osmoles in the plasma (which may be present in a subset of WGMA in which the acid is osmotically active): 

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  \text{calculated osmolality, } cP_{Osm} =(2\times P_{Na})+P_{urea}+P_{glucose}
  (\#eq:calcOsm)
\end{equation}

\begin{equation}
  \text{osmolar gap, } OG = \text{measured } P_{Osm} - cP_{Osm}
  (\#eq:Osmgap)
\end{equation}</div>\EndKnitrBlock{eqnpanel}

Historically, it has been technically difficult to measure urinary ammonium.  Therefore the *urinary* anion gap has been used as a proxy measure - either in isolation or in combination with the urinary osmolar gap (Kraut & Madias, 2012; Sharma et al., 2015): 

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  \text{urinary anion gap, } UAG=U_{Na}+U_{K}-U_{Cl}
  (\#eq:urineAGap)
\end{equation}

\begin{equation}
  \text{calculated urinary osmolality, } cU_{Osm} = 2 \times (U_{Na}+U_{K})+U_{urea}+U_{glucose}
  (\#eq:calcUOsm)
\end{equation}

\begin{equation}
  \text{urinary osmolar gap, } UOG=\text{measured } U_{Osm} - cU_{Osm}
  (\#eq:UOsGap)
\end{equation}

\begin{equation}
  \text{urinary cations, } U_{cations}=\frac{U_{Osm}-U_{urea}-U_{glucose}}{2}
  (\#eq:UCat)
\end{equation}

\begin{equation}
  \text{calculated urinary ammonium, } cU_{NH_{4}}\approx UAG \approx \frac{UOG}{2} \approx U_{cations}-(U_{Na}+U_{K})
  (\#eq:UCalcNH)
\end{equation}</div>\EndKnitrBlock{eqnpanel}

UAG normal range is positive 30 -- 50.  

### Causes of a metabolic acidosis

#### WGMA

<!-- +  **G** \* glycols *ethylene glycol; propylene glycol* -->
<!-- +  **O** oxoproline -->
<!-- +  **L** L-lactate *shock, liver disease, metformin, linezolid (several weeks into Rx)* -->
<!-- +  **D** D-lactate *short bowel syndromes* -->
<!-- +  **M** \* methanol -->
<!-- +  **A** aspirin -->
<!-- +  **R** renal failure -->
<!-- +  **K** \*^?^ ketoacidosis -->

<table>
<tbody>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> G </td>
   <td style="text-align:left;"> glycols ethylene glycol; propylene glycol * </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> O </td>
   <td style="text-align:left;"> oxoproline </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> L </td>
   <td style="text-align:left;"> L-lactate shock, liver disease, metformin, linezolid (several weeks into Rx) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> D </td>
   <td style="text-align:left;"> D-lactate short bowel syndromes </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> M </td>
   <td style="text-align:left;"> methanol * </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> A </td>
   <td style="text-align:left;"> aspirin </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> R </td>
   <td style="text-align:left;"> renal failure </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> K </td>
   <td style="text-align:left;"> ketoacidosis *(?) </td>
  </tr>
</tbody>
</table>

Propylene glycol (a solvent for parenteral medications: lorazepam, diazepam, phenobarbital) is metabolised to L- and D-lactate.

\* WGMA with elevated OG = EtOH ketoacidosis, MeOH and the glycols. The OG is NOT elevated with salicylates. There is a time-dependant conversion from OG to AG following ingestion of toxic alcohol (metabolites are charged and bind to Na). Administer fomepizole early (before significant acidosis). Indications for RRT (prefer HD to HF): acidosis, renal failure, EG level \> 50 mg/L.

#### HCMA (normal gap)

+  \+ ve U AG (unable to acidify urine)
    +  *RTA type I (always)*
    +  *RTA type IV (always)*
    +  *RTA type II (sometimes) \**

+  -- ve U AG (able to acidify urine)  
    +  renal (FEHCO~3~ \> 10 -- 15 %)
        +  *RTA type II (sometimes) \**
        +  *RTA of renal insufficiency (GFR \> 15)*

    +  extrarenal (FEHCO~3~ \<\< 5 % \*\*)  
        +  *diarrhoea (GI HCO~3~ loss)*
        +  *ureteric diversion*
        +  *pancreatic secretions*
        +  *biliary secretions*

<table>
<tbody>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="3"> + VE U AG (UNABLE TO ACIDIFY URINE) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="3"> RTA </td>
   <td style="text-align:left;"> RTA type I (always) </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> RTA type IV (always) </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> RTA type II (sometimes) * </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="6"> – VE U AG (ABLE TO ACIDIFY URINE) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="2"> renal (FEHCO3 &gt; 10 – 15 %) </td>
   <td style="text-align:left;"> RTA type II (sometimes) * </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> RTA of renal insufficiency (GFR &gt; 15) </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="4"> extrarenal (FEHCO3 &lt;&lt; 5 % **) </td>
   <td style="text-align:left;"> diarrhoea (GI HCO3 loss) </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> ureteric diversion </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> pancreatic secretions </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> biliary secretions </td>
  </tr>
</tbody>
</table>

\* The UAG is positive in all distal RTA. It may be positive or negative in proximal RTA.

\*\* FEHCO~3~ also \< 5 % in dRTA.

For HCMA (Rodriguez Soriano, 2002; Kraut & Madias, 2012; Haque et al., 2012; Sharma et al., 2015).

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  FE_{HCO_{3}} = \frac{U_{HCO_{3}}}{P_{HCO_{3}}} \times \frac{P_{Creat}}{U_{Creat}}
  (\#eq:FEHCO3)
\end{equation}</div>\EndKnitrBlock{eqnpanel}

\BeginKnitrBlock{algpanel}<div class="algpanel">### Order of investigations in metabolic acidosis

1)  AG *is this a normal or wide gap acidosis*  
2)  ΔAG vs ΔHCO~3~ *in WGMA, is rise in AG proportional to fall in HCO~3~ (or is this a mixed metabolic disorder)?*  
3)  PaCO~2~ *is the fall in PaCO~2~ proportional to the fall in HCO~3~ (0.16 kPa per mM)?*  
4)  +/- OG *for a WGMA*  
5)  +/- UAG *for HCMA*  
6)  +/- FEHCO~3~ *for HCMA with --ve UAG*  
</div>\EndKnitrBlock{algpanel}

ΔAG / ΔHCO~3~ \< 1 mixed WGMA / HCMA or urinary ketone losses (DKA)
ΔAG / ΔHCO~3~ \> 2 mixed WGMA and metabolic alkalosis


### Cautions in the interpretation of UAG

i) extreme volume depletion 
    - results in low UNa and UCl
    - low UCl limits NH~4~ excretion and may therefore lead to a "spurious" positive UAG in diarrhoea  

ii) ketoacidosis 
    - unmeasured anions in the urine (β-hydroxybutyrate and acetoacetone)
    - may therefore lead to a positive UAG even though urinary NH4+ excretion is increased\...
    - ...detect this by measuring the urinary osmolar gap  

iii) glue-sniffing (toluene) 
    - unmeasured anions in the urine (hippurate) 

A +ve UAG in the context of *alkaline* urine could signify bicarbonaturia (post-vomiting, loop diuretics, post-hypercapnoea).


## Renal tubular acidosis

Free [H^+^] is nM, but we need to excrete mmoles (1 mmol / kg on Western diet), therefore must be buffered by NH~4~, PO~4~...

### Classification of RTA  

+  type II (pRTA) *impaired reabsorption of HCO3*  


+  type I (dRTA) *inability to secrete acid* 
    +  *complete dRTA systemic acidosis (impaired ammoniagenesis)* 
    +  *partial dRTA no acidosis (preserved ammoniagenesis)*  

    
+  type IV *impaired ammoniagenesis (due to hyperK); deficient aldosterone or CD abnormality*  


+  type III (mixed) *CA inhibition*  


+  RTA in CKD *HCMA when GFR \< 30; WGMA when GFR \< 15*  

### Associations

- dRTA CaP stones (alkaline urine, hypocitraturia)  
- nephrocalcinosis (in inherited but NOT acquired forms)  
- osteoporosis  

### Investigation of suspected RTA

+  UAG & FENaHCO~3~  
+  urine pH (never \< 5.5 in dRTA)  
+  in suspected pRTA 
    +  *tubular reabsorption of phosphate (TRP = 100 - FEPO~4~) \< 85 %* 
    +  *glycosuria, aminoaciduria, LMW proteinuria*  
+  in suspected dRTA 
    +  *furosemide-fludrocortisone (FF) test (failure to achieve pH \< 5.3 , 3 -- 4 hrs after 40 -- 80 mg / 1 mg)* 
    +  *UCa \> 4 mg / kg / day (or spot UCa/Cr \> 0.2) in type I RTA* 
    +  *USS / KUB (medullary nephrocalcinosis in type I RTA)* 
    +  *urinary citrate (low in type I RTA; high in type II / IV RTA)*  

### Causes

<!-- +  pRTA (isolated)  -->
<!--     +  inherited  -->
<!--     +  acquired *topiramate*   -->


<!-- +  pRTA (with Fanconi)  -->
<!--     +  inherited *NBCe1A (AR with ocular abnormalities)*  -->
<!--     +  metabolic *Wilson's, cystinosis, fructose intolerance, Dent's, mitochondrial cytopathies*  -->
<!--     +  dysproteinaemia *myeloma, LCDD, LCFS is κ in 96 %, amyloid*  -->
<!--     +  tubulointerstitial *interstitial nephritis (inc. Sjogren's), allograft rejection*  -->
<!--     +  drugs *(Abx / cART)* *tenofovir, lamivudine, aminoglycosides, outdated tetracyclines*  -->
<!--     +  drugs *(other) cisplatin, valproate, lenalinomide*  -->
<!--     +  toxins *Pb, Hg, Cd, aristolochic acid*   -->


<!-- +  dRTA  -->
<!--     +  inherited *AEI (AR), H-ATPase B1 (AR with SNHL), H-ATPase A4 (AR)*  -->
<!--     +  tubulointerstitial *chronic pyelonephritis, chronic TIN, obstructive uropathy, sickle cell, rejection*  -->
<!--     +  autoimmune *hypergammaglobulinaemia, SLE, Sjogren's, chronic active hepatitis, PBC*  -->
<!--     +  drugs *Li^+^, amphoterecin, toluene*  -->
<!--     +  nephrocalcinosis *hyperPTH, idiopathic hypercalciuria, MSK*   -->


<!-- +  type IV  -->
<!--     +  low renin *DM, NSAIDs, CNIs, β--*  -->
<!--     +  high renin *Addisons, CAH, ACEi, ARB, heparin, ketoconazole*  -->
<!--     +  abnormal CD *TIN, spiro, amiloride, trimethoprim*   -->


<!-- +  type III  -->
<!--     +  inherited *CAII (AR with osteopetrosis / cerebral calcification)*  -->
<!--     +  acquired *topiramate (CA inhibition)*   -->

<table>
<tbody>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="2"> PRTA (ISOLATED) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> inherited </td>
   <td style="text-align:left;"> inherited </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;"> acquired </td>
   <td style="text-align:left;"> topiramate </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="24"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> inherited </td>
   <td style="text-align:left;"> NBCe1A (AR with ocular abnormalities) </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="5"> metabolic </td>
   <td style="text-align:left;"> Wilson's </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> cystinosis </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> fructose intolerance </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> Dent disease </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> mitochondrial cytopathies </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="4"> dysproteinaemia </td>
   <td style="text-align:left;"> myeloma </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> LCDD </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> LCFS is κ in 96 %, </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> amyloid </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="3"> TIN </td>
   <td style="text-align:left;"> Sjogren's </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> other TIN </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> allograft rejection </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="4"> drugs (Abx / cART) </td>
   <td style="text-align:left;"> tenofovir </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> lamivudine </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> aminoglycosides </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> outdated tetracyclines </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="3"> drugs (other) </td>
   <td style="text-align:left;"> cisplatin </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> valproate </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> lenalinomide </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="4"> toxins </td>
   <td style="text-align:left;"> Pb </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> Hg </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> Cd </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> aristolochic acid </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="19"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="3"> inherited </td>
   <td style="text-align:left;"> AEI (AR) </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> H-ATPase B1 (AR with SNHL) </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> H-ATPase A4 (AR) </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="5"> TIN </td>
   <td style="text-align:left;"> chronic pyelonephritis </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> chronic TIN </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> obstructive uropathy </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> sickle cell </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> allograft rejection </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="5"> autoimmune </td>
   <td style="text-align:left;"> hypergammaglobulinaemia </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> SLE </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> Sjogren's </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> chronic active hepatitis </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> PBC </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="3"> drugs </td>
   <td style="text-align:left;"> Li+ </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> amphoterocin </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> toluene </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="3"> nephrocalcinosis </td>
   <td style="text-align:left;"> hyperPTH </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> idiopathic hypercalciuria </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> MSK </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="12"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="4"> low renin </td>
   <td style="text-align:left;"> DM </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> NSAIDs </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> CNIs </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> β– </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="5"> high renin </td>
   <td style="text-align:left;"> Addison's </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> CAH </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> ACEi / ARB </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> heparin </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> ketoconazole </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="3"> abnormal CD </td>
   <td style="text-align:left;"> TIN </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> sprionolactone / amiloride </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> trimethoprim </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="2"> TYPE III </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> inherited </td>
   <td style="text-align:left;"> CAII (AR with osteopetrosis / cerebral calcification) </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;"> acquired </td>
   <td style="text-align:left;"> topiramate (CA inhibition) </td>
  </tr>
</tbody>
</table>

Sjogrens classically causes a dRTA (but can also cause pRTA if interstitial nephritis).

Mitochondrial cytopathy: raised CK, abnormal number of microchondria (EM).

### Treatment

+  K citrate 
+  +/- NaHCO~3~ 
